Navigation Links
ABX Pentra XL 80

ProductsABX Pentra XL 80
Company Horiba ABX
Item ABX Pentra XL 80
Features 
  • Auto-sampling.
  • 5-part differential.
  • Customized dilution ratio.
  • Automatic sample re-run.
  • 26 parameters.
  • Patient data management adapted to your specific needs.
  • Optimized sample processing, ideal for workloads up to 350 samples/day.
  • Fully integrated validation station.
  • Completely automated and easy access to all menus.
Description In response to the needs of its users for onboard data management and automated sample dilution, ABX has launched the latest development in its haematology analyser range, the PENTRA XL 80. In addition to these unique new features, the PENTRA XL 80 incorporates all the key features of the PENTRA 80 including fully automated throughput of 80 samples per hour to provide a CBC + DIFF leucocyte count with over 26 parameters. The new Customised Dilution Ratio (CDR) of the PENTRA XL 80 uniquely enables automatic linearity extension and completely removes the need for manual dilution of out-of-range samples. The CDR pushes back the linearity limits with a choice of three different ratios (1/2, 1/3, 1/5) for over range samples without any operator intervention.

To provide a complete solution to laboratory requirements by treating haematology workflow with intelligence, the PENTRA XL 80 also incorporates a cutting edge fully integrated data management system that enables onboard validation of results. The Integrated Validation Station automatically provides report validation and positive and negative Delta check flagging. In addition, it undertakes patient reporting using selective results for mixing from run, re-run and manual entry.

The new analyser is also ideal for micro sampling, since the technology behind the PENTRA XL 80 is based on a patented double sampling needle and MDSS technology which results in very low sample volumes - 30l for CBC (53l for CBC+DIFF). Furthermore, as both rack and sample barcodes are read, the PENTRA XL 80 guarantees accurate sample identification. Equally importantly, end-over-end rotation of tubes prior to sampling ensures optimal sample homogenisation and result quality.

Info Horiba ABX
Customer Service: (888) 903-5001
Web site: http://www.horiba-abx.com/gb/

Related medicine products :

1. ABX Pentra 60
2. ABX Pentra 120 SPS
3. ABX Pentra 60 C+
4. ABX Pentra 80
5. ABX Pentra DX 120
6. ABX Pentra 400
7. ABX Pentra DF 120
For use with E0828 needle and gouge set and E0828 C handle. Straight gouge shape tip. Polished finish. Most popular size or model....
Set consists of one each:E0824 A replacement burr set. E0824 B handle....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
Medicine Products:
(Date:10/31/2014)... Mass. Friday. October 31, 2014 — A team ... Berkeley, and the University of California, Santa Cruz, ... (NCI) Cancer Genomics Cloud Pilot contracts with the ... large-scale analysis of The Cancer Genome Atlas (TCGA) ... the required computing resources in one cloud environment. ...
(Date:10/31/2014)... 31, 2014 Monica Williams-Murphy MD ... all too well the chaos that can occur for ... “The vast majority of Americans who come into the ... are completely unprepared for the moment and so are ... can serve as a catalyst for a family to ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... Surgery for low back pain caused by spinal stenosis ... live, a new report says. "Nearly 80 percent ... point in their lives, and about 30 million people ... problem," co-author Brook Martin, of the Dartmouth Institute of ... news release. In spinal stenosis, thickening of tissue ...
(Date:10/31/2014)... and cost, patients with early stage breast cancer ... with proton therapy versus whole breast irradiation (WBI), ... Texas MD Anderson Proton Therapy Center. ... typical patient characteristics, researchers used Medicare reimbursement codes ... of partial and whole breast irradiation therapies and ...
Breaking Medicine News(10 mins):Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3
... care in pets we offer a 20% discount on all dental ... time to maintain good dental health, you may avoid some serious and ... ... Dental Health Care is extremely important in maintaining the health and well-being ...
... military support organization Soldiers, Angels are donated to VA facilities for ... ... January 22, 2009 -- Soldiers, Angels is once again ... best support and equipment to meet their needs. With the assistance ...
... 2009 Although primary prostate surgery or radiotherapy is successful ... a recurrence of the disease, which is most often first ... biochemical recurrence affects 30% to 40% of patients after surgery. ... outside the prostate after surgery, will affect about a third ...
... may carry less risk of serious complications if stents coated ... the procedure rather than bare-metal stents, UT Southwestern Medical Center ... and in an upcoming issue of The Journal of ... multicenter trial comparing two types of commonly used stents. Stents ...
... leading provider of software and technologies for employee and ... David Ashworth as Chief Executive Officer. Mr. Ashworth, 47, ... While at Memec, he transitioned the company to a ... electronics distributor by growing annual revenues to greater than ...
... International Retail Expansion, With Near Term Focus on Top ... ExtensionIRVINE, Calif., Jan. 21 University Medical ... and efficacy-based skin and beauty care products sold at ... U.S., announced today that it has appointed Tom Roche ...
Cached Medicine News:Health News:Indian Head Animal Hospital Announces Dental Discounts for Pets through March 31st 2Health News:Soldiers' Angels Announces Special Wheelchair Covers for Veterans 2Health News:Treatments after prostate surgery reported in the Journal of Urology 2Health News:Treatments after prostate surgery reported in the Journal of Urology 3Health News:UT Southwestern researchers find drug-coated stents less risky for heart bypass patients 2Health News:David Ashworth Joins MediKeeper as CEO 2Health News:University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing 2Health News:University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing 3
(Date:10/31/2014)...  Digirad Corporation (Nasdaq: DRAD) today announced that it has ... PDII ), a healthcare commercialization services company, responding to ... company.  Digirad calls upon PDI to ... to operate in the ordinary course of business and ... debt, on acquisitions or other extraordinary transactions. Digirad believes ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6